DEF: Pharma-Bio Serv 2026 Annual Meeting Proxy Statement

Pharma-Bio Serv, Inc. has issued its definitive proxy statement for the 2026 Annual Meeting of Stockholders scheduled for May 15, 2026.

Summary

• The 2026 Annual Meeting of Stockholders is scheduled for May 15, 2026, in Boca Raton, Florida.
• Stockholders will vote on the election of one Class I director, Irving Wiesen, for a term expiring in 2029.
• Stockholders will vote on the ratification of Crowe PR PSC as the independent registered public accounting firm for the fiscal year ending October 31, 2026.
• The record date for voting eligibility was April 8, 2026, with 22,901,692 shares of common stock outstanding.
• The company reported a net loss of $100,463 for the fiscal year ended October 31, 2025.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine governance filing. While the company is attempting to modernize via AI, the persistent net losses and lack of growth in shareholder value over the last three years temper the outlook.

Positives

• The company maintains a fully independent Board of Directors.
• The Audit Committee is chaired by a designated financial expert, Howard Spindel.
• The company has invested in an AI-driven Lead Generation Technology Platform to automate business development and recruitment.

Negatives

• The company reported a net loss of $100,463 for fiscal year 2025.
• The company has experienced significant volatility in net income, swinging from a $1.3 million profit in 2023 to losses in 2024 and 2025.
• The company has not designated a lead independent director.

Risks

• The company faces risks related to liquidity, credit, operations, and regulatory compliance.
• The company is subject to potential conflicts of interest regarding related party transactions, including the AI Agreement involving a board member.
• The company's financial performance has been inconsistent, with net losses reported in the last two fiscal years.

Future Outlook

The company intends to focus on strategic expansion into new markets and mergers and acquisition activities, supported by the implementation of its new AI-driven lead generation platform.

Management Comments

• The Board believes the current leadership structure, with separate Chairman and CEO roles, allows for effective guidance and oversight.
• The Compensation Committee determined that no risks exist arising from the company's compensation policies that are reasonably likely to have a material adverse effect on the company.

Industry Context

StockSavvy.ai notes that Pharma-Bio Serv operates in a niche pharmaceutical consulting space where regulatory compliance and specialized validation services are critical. The company's pivot toward AI-driven business development reflects a broader industry trend of leveraging automation to reduce overhead and improve lead conversion in professional services.

Comparison to Industry Standards

• The company's board structure and committee composition align with standard corporate governance practices for small-cap entities.
• The use of a regional accounting firm (Crowe PR PSC) is common for companies of this size and geographic focus in Puerto Rico.
• The executive compensation structure, heavily weighted toward base salary with modest equity incentives, is typical for a company of this market capitalization.

Corporate Governance

Related Party Transactions

• The company leased office facilities in Dorado, Puerto Rico, from an affiliate of a former Chairman and major stockholder until December 31, 2025.
• The company entered into an AI Agreement with a company partially owned and managed by board member Dov Perlysky for $250,000.

Stakeholder Impact

• Shareholders are requested to vote on director election and auditor ratification.
• The company's continued net losses may impact shareholder value and future dividend potential.

Next Steps

• Hold the Annual Meeting of Stockholders on May 15, 2026.
• Ratify the selection of Crowe PR PSC as independent auditors.
• Elect Irving Wiesen as a Class I director.

Key Dates

Recommendation

The company is in a period of transition with recent net losses and a reliance on legacy business models. While the AI initiative is a positive step, the lack of clear profitability and the small market cap suggest a cautious 'hold' until the company demonstrates a return to consistent net income.

Keywords

Pharma-Bio Serv, Proxy Statement, Corporate Governance, Annual Meeting, Pharmaceutical Services, SEC Filing